$1.99
8.08% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US05479K1060
Symbol
ELUT

Aziyo Biologics Inc - Ordinary Shares - Class A Stock price

$1.99
+0.00 0.00% 1M
-1.15 36.62% 6M
-1.75 46.79% YTD
-2.07 50.99% 1Y
-5.01 71.57% 3Y
-15.01 88.29% 5Y
-15.01 88.29% 10Y
-15.01 88.29% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-0.18 8.08%
ISIN
US05479K1060
Symbol
ELUT
Industry

Key metrics

Basic
Market capitalization
$91.8m
Enterprise Value
$108.4m
Net debt
$16.6m
Cash
$8.5m
Shares outstanding
42.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.9 | 3.1
EV/Sales
4.6 | 3.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-128.1%
Return on Equity
116.6%
ROCE
551.0%
ROIC
1,056.9%
Debt/Equity
-0.6
Financials (TTM | estimate)
Revenue
$23.7m | $29.2m
EBITDA
$-19.1m | $-11.9m
EBIT
$-22.6m | $-24.7m
Net Income
$-21.5m | $-26.0m
Free Cash Flow
$-33.8m
Growth (TTM | estimate)
Revenue
-25.3% | 19.7%
EBITDA
23.9% | 42.7%
EBIT
21.2% | -1.9%
Net Income
74.1% | 51.9%
Free Cash Flow
-59.1%
Margin (TTM | estimate)
Gross
44.7%
EBITDA
-80.7% | -40.9%
EBIT
-95.4%
Net
-90.9% | -89.0%
Free Cash Flow
-142.8%
More
EPS
$-0.5
FCF per Share
$-0.8
Short interest
0.1%
Employees
51
Rev per Employee
$480.0k
Show more

Is Aziyo Biologics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Aziyo Biologics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Aziyo Biologics Inc - Ordinary Shares - Class A forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Aziyo Biologics Inc - Ordinary Shares - Class A forecast:

Buy
88%
Hold
13%

Financial data from Aziyo Biologics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
24 24
25% 25%
100%
- Direct Costs 13 13
28% 28%
55%
11 11
21% 21%
45%
- Selling and Administrative Expenses 29 29
21% 21%
123%
- Research and Development Expense 3.97 3.97
25% 25%
17%
-19 -19
24% 24%
-81%
- Depreciation and Amortization 3.49 3.49
2% 2%
15%
EBIT (Operating Income) EBIT -23 -23
21% 21%
-95%
Net Profit -22 -22
74% 74%
-91%

In millions USD.

Don't miss a Thing! We will send you all news about Aziyo Biologics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aziyo Biologics Inc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
8 days ago
GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York: Cantor Global Healthcare Conference Format: Fireside Chat...
Neutral
Seeking Alpha
20 days ago
Elutia Inc. (NASDAQ:ELUT ) Q2 2025 Earnings Conference Call August 14, 2025 5:00 PM ET Company Participants C. Randal Mills - Co-Founder, President, CEO & Director Matthew B.
Neutral
GlobeNewsWire
20 days ago
EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m.
More Aziyo Biologics Inc - Ordinary Shares - Class A News

Company Profile

Aziyo Biologics, Inc. operates as a biotechnology company which focuses on regenerative medicine in areas such as cardiology, orthopedics and other medical specialties. It offers cardiac device envelope, vascular surgery, cardiothoracic repair, orthopedics and spine, sports medicine, dermal, and wound care. The company was founded on August 6, 2015 and is headquartered in Silver Spring, MD.

Head office United States
CEO Charles Mills
Employees 51
Founded 2015
Website elutia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today